1. Linsenmeyer TA, Culkin D. APS recommendations 
for the urological evaluation of patients with 
spinal cord injury. J Spinal Cord Med 1999;22(2):139-142.

  2. Hicken BL, Putzke JD, Richards JS. Bladder 
management and quality of life after spinal cord injury. Am J Phys Med Rehabil 2001;80:

  3. Sauerwein D. Urinary tract infection in patients with neurogenic bladder dysfunction. Int J Antimicrob Agents 2002;19:592-597.

  4. Zorn BH, Montgomery H, Pieper K, et al. 
Urinary incontinence and depression. J Urol 1999;

  5.  Hu TW, Wagner TH, Bentkover JD, et al. Costs of urinary incontinence and overactive bladder in the United States: a comparative study. Urology 2004;63:461-465.

  6.  Rackley R, Vasavada S, Firoozi F, et al. Neurogenic bladder. Medscape Reference. Updated November 23, 2011. Accessed March 7, 2012.

  7. Semins MJ, Chancellor MB. Diagnosis and management of patients with overactive bladder syndrome and abnormal detrusor activity. Nat Clin Pract Urol 2004;1(2):78-84.

  8. Kennelly MJ, DeVoe WB. Overactive bladder: pharmacologic treatments in the neurogenic population. Rev Urol 2008;10(3):182-191.

  9. Kershen RT. Algorithms for the management of overactive bladder. Curr Urol Rep 2009;10(5):352-361.

  10. Benevento BT, Sipski ML. Neurogenic bladder, neurogenic bowel, and sexual dysfunction in people with
spinal cord injury. Phys Ther 2002 Jun;82(6):601-612.

  11. Weld KJ, Dmochowski RR. Association of level of injury and bladder behavior in patients with post-traumatic spinal cord injury. Urology 2000;55(4):490-494.

  12. Wyndaele JJ, Kovindha A, Madersbacher H, et al; Committee 10 on Neurogenic Bladder and Bowel of the International Consultation on Incontinence 2008-2009. Neurologic urinary incontinence. Neurourol Urodyn 2010;29(1):159-164.

  13. Abrams P, Andersson KE, Birder L, et al. Fourth International Consultation on Incontinence Recommendations of the International Scientific Committee: Evaluation and treatment of urinary incontinence, pelvic organ prolapse, and fecal incontinence. Neurourol Urodyn 2010;29:213-240.

  14. Smith JH, Berghmans B, Burgio K, et al. Committee 12. Adult conservative management. In: Abrams P, Cardozo L, Khoury S, Wein A, eds. Incontinence: 4th International Consultation on Incontinence. Paris, France: Health Publication Ltd; 2009:1025-1120.

  15. Wyndaele JJ, Kovindhaa A, Madersbacher H, et al. 
Committee 10. Neurologic urinary and faecal incontinence. In: Abrams P, Cardozo L, Khoury S, Wein A, eds. Incontinence: 4th International Consultation on Incontinence. Paris, France: Health Publication Ltd; 2009:793-960.

  16. Yamaguchi O, Nishizawa O, Takeda M, et al; Neurogenic Bladder Society. Clinical guidelines for overactive bladder. Int J Urol 2009;16(2):126-142.

  17. Newman DK, Willson MM. Review of intermittent catheterization and current best practices. Urol Nurs 2011;31:12-28.

  18. Linsenmeyer TA, Bodner DR, Creasey GH, et al. Bladder management for adults with spinal cord injury. A clinical practice guideline for health-care providers. J Spinal Cord Med 2006;29(5):527-573.

  19. Cardenas DD, Moore KN, Dannels-McClure A, et al. Intermittent catheterization with a hydrophilic-coated catheter delays urinary tract infections in acute spinal cord injury: a prospective, randomized, multicenter trial. PM R 2011;3(5):408-417.

  20. Singh G, Thomas DG. The female tetraplegic: an admission of urological failure. Br J Urol 1997;79:708-712.

  21. Song GW, Fam BA, Lee IY, et al. Management of neurogenic bladder in female spinal cord injury patients. 
J Am Paraplegia Soc 1984;7(1):4-7.

  22. Ginsberg DA. Management of the neurogenic bladder in the female patient. Curr Urol Rep 2006;7(5):423-428.

  23. Stöhrer M, Blok B, Castro-Diaz D, et al. EAU guidelines on neurogenic lower urinary tract dysfunction. Eur Urol 2009;56:81-88.

  24. Stöhrer M, Mürtz G, Kramer G, et al. Propiverine compared to oxybutynin in neurogenic detrusor overactivity—results of a randomized, double-blind, multicenter clinical study. Eur Urol 2007;51(1):235-242. 

  25. Horstmann M, Schaefer T, Aguilar Y, et al. Neurogenic bladder treatment by doubling the recommended antimuscarinic dosage. Neurourol Urodyn 2006;25(5):441-445.

  26. Van Kerrebroeck PE, Amarenco G, Thüroff JW, et al. Dose-ranging study of tolterodine in patients with detrusor hyperreflexia. Neurourol Urodyn 1998;17(5):499-512.

  27. Cameron AP, Clemens JQ, Latini JM, McGuire EJ. Combination drug therapy improves compliance of the neurogenic bladder. J Urol 2009;182(3):1062-1067. 

  28. Novara G, Galfano A, Secco S, et al. A systematic review and meta-analysis of randomized controlled trials with antimuscarinic drugs for overactive bladder. Eur Urol 2008;54(4):740-763.

  29. Cole AT, Fried FA. Favorable experiences with imipramine in the treatment of neurogenic bladder. J Urol 1972;107(1):44-45.

  30. Mohfouz W, Corcos J. Management of detrusor external sphincter dyssynergia in neurogenic bladder. Eur J Phys Rehabil Med 2011;67:639-650.

  31. Schurch B, Stöhrer M, Kramer G, et al. 
Botulinum-A toxin for treating detrusor hyperreflexia in spinal cord injured patients: a new alternative to anticholinergic drugs? Preliminary results. J Urol 2000;164:692-697. 

  32. Schurch B, de Seze M, Denys P, et al. Botulinum toxin type a is a safe and effective treatment for neurogenic urinary incontinence: results of a single treatment, randomized, placebo controlled 6-month study. J Urol 2005;174:196-200. 

  33. Cruz F, Herschorn S, Aliotta P, et al. Efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: a randomised, double-blind, placebo-controlled trial. Eur Urol 2011;60:742-750.

  34. Karsenty G, Reitz A, Lindemann G, et al. Persistence of therapeutic effect after repeated injections of botulinum toxin type A to treat incontinence due to neurogenic detrusor overactivity. Urology 2006;68(6):1193-1197. 

  35. Gamé X, Khan S, Panicker JN, et al. Comparison of the impact on health-related quality of life of repeated detrusor injections of botulinum toxin in patients with idiopathic or neurogenic detrusor overactivity. BJU Int 2011;107:1786-1792.

  36. Seoane-Rodríguez S, Sánchez R-Losada J, Montoto-Marqués A, et al. Long-term follow-up study of intraurethral stents in spinal cord injured patients with detrusor-sphincter dyssynergia. Spinal Cord 2007;45:621-626. 

  37. Tan HJ, Stoffel J, Daignault S, et al. Ileovesicostomy for adults with neurogenic bladders: complications and potential risk factors for adverse outcomes. Neurourol Urodyn 2008;27:238-243.